Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tobicom
- Development stage
- Unknown
- Lead developer
- ICA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tobicom is an approved ophthalmic nutritional supplement and pharmaceutical combination product developed by Ahn-Gook Pharmaceutical and manufactured/marketed by ICA Biotechnological & Pharmaceutical in Vietnam. It is formulated as an oral capsule containing sodium chondroitin sulfate, retinol palmitate (vitamin A), choline hydrogen tartrate, riboflavin (vitamin B2), and thiamine hydrochloride (vitamin B1). Tobicom is indicated for eye fatigue, keratitis, ophthalmoplegia, amblyopia during lactation, nyctalopia (night blindness), and as a nutritional supplement for decreased vision. Sodium chondroitin sulfate stabilizes intracellular collagen to support ocular muscle neurons and optic lens flexibility, while the vitamin and choline components support epithelial tissue maintenance and vision.
- Brand names
- Tobicom
- Other names
- choline bitartrate + retinol palmitate + riboflavin + sodium chondroitin sulfate + thiamine hydrochloridecholine hydrogen tartrate + retinol palmitate + riboflavin + sodium chondroitin sulfate + thiamine hydrochloride
02
Targets
CD44 (CD44 antigen)CHAT (Choline acetyltransferase)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)RFK (Riboflavin kinase)TPK1 (Thiamine pyrophosphokinase 1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Tobicom.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tobicom.